Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528861 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
A Phase 2 study, sponsored by Allakos.
- Terminated
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT05528861 is a Phase 2 study that was terminated before completion, run by Allakos. The registered enrollment target is 127 participants.
The verdict
NCT05528861, a Phase 2 study, was terminated before completion, sponsored by Allakos.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 6 doses of subcutaneous lirentelimab.
Interventions
- OTHER Placebo
- DRUG Lirentelimab (AK002)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2024-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05528861
The ClinicalTrials.gov registry entry for NCT05528861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05528861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05528861 about?
NCT05528861 is a clinical study titled "A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria. Subjects who complete the randomized, double-blind, placebo-c...
What is the current status of trial NCT05528861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2022-10-26. Estimated completion is 2024-04-18.
What interventions are being tested in trial NCT05528861?
The interventions under investigation include: Placebo (OTHER), Lirentelimab (AK002) (DRUG).
Who is sponsoring clinical trial NCT05528861?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.